Advertisement

Topics

FDA approves Herceptin biosimilar as US patent expires

08:10 EDT 14 Jun 2019 | pharmaphorum

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month, paving the way for cut-price competition in the US at last. ...

Original Article: FDA approves Herceptin biosimilar as US patent expires

NEXT ARTICLE

More From BioPortfolio on "FDA approves Herceptin biosimilar as US patent expires"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...